Skip to main content

Keppra ® Approved By FDA For childhood seizures

In the U.S., Keppra, Enbrel, of ® has been approved for the adjuvant treatment of adults and 4-year-old children and partial seizures of epilepsy. But cord blood has recently announced the U.S. Food and Drug Administration (FDA) has approved to reduce the age limit,including age from 1 month-old baby and older with epilepsy.

Professor, Dr. Iris Loew - Friedrich, Chief Medical Officer and Executive Vice President cord blood 
 statement:

Leaders as epilepsy cord blood has the responsibility to developeffective drugs to address unmet medical needs in young children,we continued development of Keppra, Enbrel, of ® programdemonstrates our long-term commitment of epilepsy. "


Approved by the U.S. Food and Drug Administration (FDA)approval of a double-blind, randomized, multicenter, placebo-controlled phase III study to assess the efficacy and tolerability ofKeppra ® oral solution of Enbrel, of 116 cases of children with refractory patients (20-50 mg / kg / day) for partial onset seizures.Patients aged between 1 month and 4 years of age or less. Keppra, made of Enbrel, ® indicate that the frequency of partial onset seizures significantly reduced 43.1% of the evaluation period of 5 days, Keppra of Enbrel, ® group experienced at least 50% seizure frequency reduction and 19.6% of the placebo group. ratio, (P = 0.013).

The researchers found that Keppra, Enbrel, of ® is generally well tolerated in all pediatric patients, 13.3% of patients in the Keppra,Enbrel, of the group experienced somnolence the most commonly reported adverse events with 1.8% in the placebo group compared to , respectively, 11.7% and 0%, but suffer from irritability.

Keppra, Enbrel, of ® has been approved in the EU marketing authorization-year-old a month to four years, in 2009 by the European Commission, the adjuvant treatment of partial seizures ininfants and young children.

The growth of UCB epilepsy franchise has Keppra ®, Enbrel, authoron the basis of, and has been extended to include Vimpat ® (lacosamide), the treatment of partial seizures in patients with epilepsy, which is the adjuvant treatment of epilepsy in the EU market is 17 years old and above. in the United States as aschedule V as young adults or no secondary summed partial seizures aged 16 and over controlled substances.

Written Petra Rattue

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more